Boston – May 3, 2017 – Cooley advised ERYTECH Pharma on a private placement of its ordinary shares to qualified investors in the US and Europe. Total gross proceeds to ERYTECH were approximately €70.5 million.
ERYTECH, based in Lyon, France, with US headquarters in Cambridge, MA, is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s ordinary shares are listed on Euronext Paris.
Cooley advised ERYTECH on its €25 million private placement in 2015 and its €10 million private placement in 2016.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.